References of "Smelten, Nicole"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCholecaciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study
DELANAYE, Pierre ULg; WEEKERS, Laurent ULg; WARLING, Xavier et al

in Nephrology Dialysis Transplantation (2013), 28(7), 1779-1786

Background. The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether ... [more ▼]

Background. The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned. The objective of this randomized double-blinded study is to assess whether cholecalciferol therapy can increase serum 25-hydroxyvitamin D [25(OH)D] levels in haemodialysed patients and the safety implications of this therapy on certain biological parameters and vascular calcifications score. Methods. Forty-three haemodialysis patients were randomized to receive placebo or cholecalciferol (25 000 IU) therapy every 2 weeks. The biological parameters, serum calcium, phosphorus, 25(OH)D and parathormone (PTH) levels, were monitored monthly for 12 consecutive months. Vascular calcifications were assessed by lateral X-ray radiography. Results. At baseline, the mean serum 25(OH)D levels were low and similar in both groups. Thirty patients (16 treated and 14 placebo) completed the study: 11 patients died (5 placebo and 6 treated), 1 patient dropped out and 1 patient was transplanted (both from the placebo group). After 1 year, the percentage of 25(OH)D deficient patients was significantly lower in the treated group. None of the patients developed hypercalcaemia. The PTH levels tended to increase over the study period under placebo and to decrease in the cholecalciferol group. The median changes in PTH levels from baseline to 1 year were statistically different between the two groups [+80 (−58 to 153) and −115 (−192 to 81) under placebo and cholecalciferol treatment, respectively, P = 0.02].The calcification scores increased equivalently in both groups (+2.3 per year). Conclusions. Cholecalciferol is effective and safe, and does not negatively affect calcium, phosphorus, PTH levels and vascular calcifications. Additional studies are needed to compare the impacts of nutritional and active vitamin D agents on vascular calcification and mortality. [less ▲]

Detailed reference viewed: 33 (10 ULg)
Full Text
Peer Reviewed
See detailL'insuffisance rénale et sa prise en charge
Krzesinski, Jean-Marie ULg; DELANAYE, Pierre ULg; Smelten, Nicole ULg et al

in Revue Médicale de Liège (2008, March 13)

Chronic kidney disease is a worldwide growing problem, especially nowadays due to 3 factors very often encountered together (old age, diabetes mellitus and arterial hypertension) A multidisciplinary ... [more ▼]

Chronic kidney disease is a worldwide growing problem, especially nowadays due to 3 factors very often encountered together (old age, diabetes mellitus and arterial hypertension) A multidisciplinary approach is needed to reduce this epidemic with important health implication. This needs of course well trained health partners. On the occasion of the world kidney day on March 2008, five lectures were given on the topic. The lecturers have insisted on the up to date management of chronic kidney insufficiency, a serious problem of public health. [less ▲]

Detailed reference viewed: 66 (5 ULg)